NICE
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care.
NICE guidelineCOVID-19 rapid guideline: managing COVID-19 symptoms in the community
Initial management: use simple non-drug measures, for example taking honey
- NICE guideline
COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response
The purpose of this Guidelines summary is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. It also aims to enable services to make the best use of NHS resources. For information on protecting staff from ...
- NICE guideline
COVID-19 rapid guideline: pneumonia in adults
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic.
- NICE guideline
COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources
- NICE guideline
COVID-19 rapid guideline: cystic fibrosis
The purpose of this Guidelines summary is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic.
- NICE guideline
COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)
The purpose of this summary is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources. For more detailed information, please refer to the full guideline.
- NICE guideline
COVID-19 rapid guideline: severe asthma
The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.
- NICE guideline
NICE tinnitus guideline
For people with long-standing tinnitus who have delayed accessing care, aim to find out the reason for the delay and why they are accessing care now. This could involve, for example, asking questions about lifestyle factors or changes in health.
- NICE guideline
NICE impetigo guideline
This guideline sets out an antimicrobial prescribing strategy for adults, young people, and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.
- NICE guideline
NICE Leg ulcer infection: antimicrobial prescribing guideline
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
- NICE guideline
NICE asthma guideline: diagnosis and monitoring
A concise summary on the initial assessment, diagnosis, and monitoring of asthma in adults, young people, and children. Includes assessment algorithms.
- NICE guideline
NICE headache guideline
This easy-to-read summary of NICE's guideline explores the diagnosis and management of tension, migraine, cluster, and medication overuse headaches.
- NICE guideline
NICE CKS—head lice
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting. Areas covered include: treatment and management, advantages and disadvantages of treatment options, information and advice for those with the condition. Please refer to the ...
- NICE guideline
NICE CKS—constipation in adults
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title, it therefore only covers the information relevant to this setting, and is deliberately concise. Areas covered in the summary include: advice for those with the condition, management (short-duration and chronic), secondary causes of the ...
- NICE guideline
NICE CKS—warts and verrucae
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting. Areas covered include: an overview of the condition, differential diagnoses, advice for those with the condition, and treatment. Please refer to the full guideline ...
- NICE guideline
NICE/PHE pneumonia: antimicrobial prescribing guideline
This summary covers an antimicrobial prescribing strategy for patients with community-acquired pneumonia.
- NICE guideline
NICE pneumonia guideline
This Guidelines summary covers diagnosis and management of pneumonia in adults, including assessment and treatment
- NICE guideline
NICE pneumonia guideline
This summary covers diagnosis and management of pneumonia in adults, including assessment and treatment.
- NICE guideline
NICE/PHE cellulitis and erysipelas: antimicrobial prescribing
This summary covers an antimicrobial strategy for patients with cellulitis and erysipelas
- NICE guideline
NICE antibiotics for COPD exacerbations guideline
This concise summary covers what to be aware of when considering antimicrobials for an acute exacerbation of COPD to avoid unnecessary prescribing.
